Malaria Pregnancy and Childbirth
Conditions
Interventions
Mefloquine
Sponsors
University of Kisangani
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Pregnant women who will : - begin antenatal visits in medical facilities selected from gestational age between 16 and 18 weeks of amenorrhea, - have not yet received SP prophylaxis during ongoing pregnancy - sign their consent form.
Exclusion criteria
Exclusion criteria: Pregnant women with : - positive HIV serology, - story of morbid neurological and psychiatric, - story of SP allergy - of antimalarial drug(s) use within 15 days prior to selection will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Mefloquine will be well tolerated by Kisangani pregnant women; - Mefloquine will be more effective than SP in pregnant women in Kisangani. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Mefloquine Side-effects will be less frequent and minors, easy to control; - The prevalence of maternal anemia at delivery will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine; - Placental malaria parasitemia will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine; - The prevalence of low birth will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine. | — |
Countries
Democratic Republic of the Congo
Contacts
Public ContactNguma Jean Didier Bosenge
Searcher
Outcome results
None listed